A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

被引：11
|
作者：
Hertzberg, Mark
Ku, Matthew
Catalani, Olivier
Althaus, Betsy
Simko, Stephen
Gregory, Gareth P.
机构：
[1] Prince Wales Hosp, Sydney, NSW, Australia
[2] St Vincents Hosp, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Monash Univ, Sch Clin Sci Monash Hlth, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS7575
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7575
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
    Zinzani, Pier Luigi
    Pellegrini, Cinzia
    Gandolfi, Letizia
    Stefoni, Vittorio
    Quirini, Federica
    Derenzini, Enrico
    Broccoli, Alessandro
    Argnani, Lisa
    Pileri, Stefano
    Baccarani, Michele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06): : 462 - 466
  • [32] Glofitamab plus Polatuzumab Vedotin demonstrates durable responses and a manageable safety profile in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Dietrich, S.
    Hutchings, M.
    Avigdor, A.
    Sureda, A.
    Terol, M. J.
    Bosch, F.
    Corradini, P.
    Larsen, Stauffer T.
    Dominguez, Rueda A.
    Skarbnik, A.
    Jorgensen, J.
    Goldschmidt, N.
    Gurion, R.
    Zinzani, P. L.
    Pinto, A.
    Cordoba, R.
    Bottos, A.
    Huang, Z.
    Simko, S.
    Relf, J.
    de L'Etang, Filezac A.
    Sellam, G.
    Gritti, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 209 - 209
  • [33] Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial
    de Vos, Sven
    Reagan, Patrick M.
    Patel, Manish R.
    Saba, Nakhle S.
    Mortlock, Andrew
    Cerec, Virginie
    Munugalavadla, Veerendra
    Acar, Melih
    Nuttall, Barrett
    Jenkins, David
    White, Rafael
    Callahan, Megan
    Forcina, Alessandra
    Roschewski, Mark
    Flinn, Ian W.
    BLOOD, 2022, 140 : 6635 - 6637
  • [34] A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage
    Toubai, Tomomi
    Kuroda, Junya
    Suehiro, Youko
    Mishima, Yuko
    Sunami, Kazutaka
    Kato, Koji
    Uoshima, Nobuhiko
    Kumode, Takahiro
    Ota, Ai
    Mitsuki, Kaori
    Yokota, Daisuke
    Sano, Yuri
    Terui, Yasuhito
    BLOOD, 2023, 142
  • [35] Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R)
    Hernandez-Ilizaliturri, F. J.
    Deeb, G.
    Zinzani, P. L.
    Pileri, S. A.
    Malik, F.
    Macon, W. R.
    Witzig, T. E.
    Goy, A.
    Czuczman, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma
    Forero-Torres, Andres
    Bartlett, Nancy L.
    Nasta, Sunita D.
    Northfelt, Donald
    Beaven, Anne
    Myint, Han
    Whiting, Nancy C.
    Drachman, Jonathan G.
    Moskowitz, Craig H.
    BLOOD, 2009, 114 (22) : 243 - 244
  • [37] Rituximab, gemcitabine and oxaliplatin (R-GEMOX):: A promising salvage regimen for refractory/relapsed B-cell lymphoma.: A pilot study.
    El Gnaoui, T
    Belhadj, K
    Joly, B
    Rahmouni, A
    Gaillard, I
    Diviné, M
    Copie-Bergman, C
    Allain, A
    Reyes, F
    Haioun, C
    BLOOD, 2003, 102 (11) : 299B - 299B
  • [38] Phase III trial of bendamustine plus rituximab for relapsed or refractory diffuse large B-cell lymphoma in Japan
    Kiguchi, Toru
    Terui, Yasuhito
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Matsumura, Itaru
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Tobinai, Kensei
    Fukushima, Koji
    Murayama, Kayoko
    ANNALS OF ONCOLOGY, 2021, 32 : S304 - S304
  • [39] Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
    Yanfei Liu
    Lingyan Ping
    Yuqin Song
    Yongjing Tang
    Wen Zheng
    Weiping Liu
    Zhitao Ying
    Chen Zhang
    Meng Wu
    Feier Feng
    Ningjing Lin
    Meifeng Tu
    Jun Zhu
    Yan Xie
    BMC Medicine, 22
  • [40] Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
    Liu, Yanfei
    Ping, Lingyan
    Song, Yuqin
    Tang, Yongjing
    Zheng, Wen
    Liu, Weiping
    Ying, Zhitao
    Zhang, Chen
    Wu, Meng
    Feng, Feier
    Lin, Ningjing
    Tu, Meifeng
    Zhu, Jun
    Xie, Yan
    BMC MEDICINE, 2024, 22 (01)
12345